Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.

Pills and tablets

On 8 March 2018, the London School of Hygiene & Tropical Medicine (LSHTM) announced the start of a major new global study, the 4-year Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE) project.

By identifying the leading causes of fever in sub-Saharan Africa and Asia and how fever patients are cared for, FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.

Funded by UKAid from DFID, FIEBRE will be conducted by LSHTM with the Liverpool School of Tropical Medicine, the Universities of Oxford, Barcelona, and Otago, as well as partner institutions within five study countries – Laos, Malawi, Mozambique, Myanmar and Zimbabwe.

MORU’s Lao PDR Unit, LOMWRU, and the Microbiology Laboratory team within Mahosot Hospital, Vientiane, will work with Vientiane Provincial Hospital for the Laos arm of this multicentre study. In addition, Yoel Lubell of MORU MAEMOD will coordinate the biomarker investigations, so that by its end, the study will have a better idea as to which biomarkers best distinguish between viral and bacterial infections, and which (if any) can predict severe outcomes.

“There is an urgent need to understand the aetiologies of fevers across Asia and Africa with consensus protocols to facilitate between country comparisons, that have so far eluded us, to inform patient treatment policies,” explained Oxford Prof Paul Newton, LOWMRU Director. “We will work to recruit and diagnose inpatients and outpatients to improve our understanding of the causes of fever in the Mekong River valley and how these compare with other countries and to work for these results to be translated into health policy.”

David Mabey, Professor of Communicable Diseases at the LSHTM and Principal Investigator of the FIEBRE project, said: “The world has made great strides in tackling malaria. Surprisingly, there has been limited research on other potential causes of febrile illness, such as infections by bacteria, viruses, and fungi, and the WHO does not provide specific guidance on the management of non-malarial fevers.

“We want to identify the treatable and preventable causes of fever in children and adults in Africa and Asia, and to identify those most at risk of different infections. Our goal is to develop guidelines that can be a blueprint for the effective management of patients with fever in different settings.”

Read the full LSHTM story announcing the FIEBRE study Major new project to reveal leading causes of fever in sub-Saharan Africa and Asia.

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.